In a report released on May 6, Lili (Aurélie) Nsongo from Leerink Partners maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a price target of $12.00.
Lili (Aurélie) Nsongo has given her Buy rating due to a combination of factors that highlight Voyager Therapeutics’ promising pipeline and financial stability. The company is making significant progress in its internal pipeline, particularly with the ongoing dosing in the Phase 1/2 study of the anti-tau antibody VY7523 for Alzheimer’s disease, with tau-PET imaging data expected in the second half of 2026. Additionally, Voyager plans to submit an IND for their siRNA therapy VY1706 for Alzheimer’s disease in 2026, indicating a strong focus on advancing their therapeutic candidates.
Furthermore, Voyager Therapeutics has strategic partnerships that could yield substantial financial milestones. The company anticipates up to $35 million in regulatory and clinical milestones from its FXN and GBA1 programs, despite the discontinuation of two discovery-stage programs by its partner NBIX. Financially, Voyager reported a solid cash position of $295 million, which supports its operations through mid-2027, excluding potential milestone payments. These factors, combined with a slight adjustment in the price target from $13 to $12, underpin the Buy rating, reflecting confidence in the company’s future growth and strategic direction.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.
VYGR’s price has also changed dramatically for the past six months – from $7.280 to $3.250, which is a -55.36% drop .